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Primary splenic lymphoma (PSL) is often defined as
generalized lymphoma with splenic involvement as the domi-
nant feature. It is a rare disease that comprises approximately
1% of all malignant lymphomas. We investigated three cases
of non-Hodgkin's splenic lymphoma that had different clinical
features on presentation. The patients' survival times from
diagnosis ranged from 59 to 143 months, without evidence of
relapse after splenectomy and chemotherapy, with or without
radiotherapy. This data suggest that PSL is potentially curable.
Further studies are needed to evaluate the impact that different
treatment modalities without splenectomy have on patient
survival.
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INTRODUCTION
Generalized lymphoma with splenic involve-
ment as the dominant feature is known as pri-
mary splenic lymphoma (PSL); however, this
definition is controversial. PSL is a rare disease
with only 1% of all malignant lymphomas re-
ported to be PSL. Additionally, there have been
very few reported cases in Korea.
1,2 However,
about 20% of all lymphoma patients seen at our
hospital have had evidence of splenic involve-
ment.
3
In this study, we report three cases of PSL with
variable clinical presentations and the excellent
results different therapies had on theses patients'
survival times.
CASE REPORT
Case 1
A 58-year-old woman presented on July 8, 1997
with indigestion for 20 days and left upper quad-
rant (LUQ) pain for one week. She had taken
antihypertensive medications for two years. Her
examination was significant for direct LUQ ten-
derness and absence of fever, night sweats, weight
loss, organomegaly, or lymphadenopathy. Signifi-
cant laboratory data included an elevated lactate
dehydrogenase (LDH) level of 180 IU/dL (refer-
ence value 56-123 IU/dL) with an elevated LD 3,
4 fraction, and a β2-microglobulin level of 3.4 mg/
dL. Esophagogastroduodenoscopy revealed a fun-
dal mass or external compression of the fundus,
and a barium study of the upper gastrointestinal
tract showed an external mass. Computed tomo-
graphy (CT) of the abdomen showed a huge
splenic mass with a homogenous high-density
area, including a portion of low-density without
evidence of perisplenic spread (Fig. 1A). A benign
splenic tumor was suspected and the patient
underwent splenectomy. The spleen weighed 442
g and measured 12.5 × 8 × 7 cm. On gross exami-
nation, a grayish-yellow nodular capsule was
noted in the lateral border without perisplenic
invasion or any enlarged hilar lymph nodes. The
exposed cut surface showed a bulging, well-
demarcated grayish-yellow nodular solid mass,
measuring 12 cm in the largest dimension (Fig. 2).
Histopathology confirmed diffuse large B-cell
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lymphoma (Fig. 3A, B) with positive expression of
L26/CD79a (Fig. 3C), and no expressions of
UCHL1, CD3, and granzyme upon immunohisto-
chemical staining.
Neck & chest CT scanning and whole body
bone scanning revealed no abnormalities. Bone
marrow aspiration & biopsy did not reveal any
evidence of lymphoma. The lymphoma was
staged at Ann Arbor stage ISEA and Ahmann stage
I. The patient received six cycles of CHOP
(cyclophosphamide, doxorubicin, vincristine, and
prednisone) chemotherapy, and has been in
complete remission without relapse for 88 months.
Case 2
A 53-year-old man was admitted in December
1992 with intermittent left flank discomfort that
had persisted for four months. He had a history
of pulmonary tuberculosis treated with anti-
tuberculosis medications 30 years ago. He was
relatively well until four months prior to admis-
sion, when the left flank and abdominal discom-
fort developed. No significant findings were noted
on physical examination. Laboratory findings
showed no cytopenia, normal levels of LDH and
β2-microglobulin, but an elevated ESR (erythro-
cyte sedimentation rate, Westergren: 24 mm/hr).
An abdominopelvic CT scan revealed a large, rela-
tively homogenous hypo-attenuating lesion (mea-
suring 8×7×9 cm) in the LUQ abutting the pan-
creatic tail & inferior pole of the spleen. This
lesion was localized and capsulated with either
internal necrosis or hemorrhage (Fig. 1B). Several
nodal areas of about 1 cm in diameter were noted
in the left para-aortic area slightly above the left
renal hilar level. Neck and chest CT scans and a
whole body bone scan were normal. Splenectomy,
distal pancreatectomy, and segmental resection of
the transverse colon revealed a large irregular
oval shaped mass (9×8×7 cm) in the enlarged
spleen (13×10×8 cm) and tail of pancreas (3×2.5×2
cm), with the spleen weighing only 570 g. The
mass adhered to the transverse colon. The Ann
Arbor stage was IISEA and the Ahmann stage of
Fig. 2. Gross examination of the resected spleen of Case
1. The exposed cut surface shows a bulging, well-
demarcated grayish-yellow nodular solid mass, measuring
12 cm in the largest dimension. Multifocal grayish-yellow
necrotic foci are present. The splenic parenchyma is nearly
replaced by this lesion.
Fig. 1. Computed tomography (CT) scans of each case. A) Case 1- a huge splenic mass with homogenous high-density
areas, including an area of low-density without perisplenic spread. B) Case 2- a well-localized and capsulated splenic
mass with internal necrosis or hemorrhage and partial bulging of the pancreatic tail portion at the junctional lesion with
spleen. C) Case 3- a heterogeneous, lobulated splenic mass measuring 10×8×8 cm with bulging contours, necrotic foci
and focal calcification.
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splenic lymphoma was III. Histology of the re-
sected spleen, pancreas, and colon revealed non-
Hodgkin's lymphoma of the diffuse large B-cell
type. Postoperatively, the patient received six
cycles of CHOP chemotherapy and radiotherapy
to the left abdomen (total dose of 3,060 cGy).
While in complete remission, he visited the emer-
gency room in October 1993 with a left ureteral
stone attack, which was relieved after conserva-
tive treatment. He was noted to be in complete
remission at the time of follow-up, 143 months
after diagnosis.
Case 3
A 52-year-old woman was admitted in Decem-
ber 1999 with a 6-month history of anorexia and
general weakness. She had previously visited a
hospital in Brazil where she underwent an abdo-
minal CT scan, which showed a splenic mass. She
then came to Korea for further evaluation and
treatment.
Twenty-eight years prior to admission, she un-
derwent dilatation & evacuation three times for a
hydatidiform mole. Twenty-seven years prior to
admission, she was diagnosed with pulmonary
tuberculosis and she received anti-tuberculosis
medications. Twenty-six years before admission,
she was diagnosed with choriocarcinoma and she
underwent total abdominal hysterectomy with
adjuvant chemotherapy.
At the time of admission, she complained of
generalized weakness, fatigue, chills, sore throat,
night sweats, mild fever, productive cough, and
poor oral intake but denied weight loss. Multiple
small cervical lymphadenopathy without spleno-
megaly was detectable. Significant laboratory data
included a hemoglobin level of 9.6 g/dL, hema-
tocrit of 28%, total leukocyte count of 7,900/uL
(differential: neutrophils, 57%: lymphocytes, 23%:
monocytes, 19%: eosinophil, 1%), and a platelet
count of 83,000/uL. The CT scan of the abdomen
taken in Brazil revealed a heterogeneous lobulated
splenic mass measuring 10×8×8 cm with bulging
contours, necrotic foci, and focal calcification (Fig.
1C). Angiosarcoma, malignant lymphoma, and
metastatic tumor were considered in the differ-
ential diagnosis. Bone marrow aspiration and
biopsy revealed no abnormal cell infiltration.
The patient then underwent splenectomy for
diagnosis. Intra-operatively, the spleen was found
to be enlarged and congested, and its cut surface
Fig. 3. Histopathologic findings of Case 1. A) Mass border
on low power (×100) showing an expanding growth
pattern of tumor cells. B) Mass on high power (×400)
showing non-Hodgkin's lymphoma, diffuse large B-cell
type. Tumor cells have large nuclei, open chromatin, and
prominent nucleoli. C) Immunohistochemical stain for L26
(B-cell marker) (×200) showing prominent immunoposi-
tivity to the tumor cells.
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was grayish-yellow with focal necrosis. There was
a 1-cm sized accessory spleen that was also
resected. Gross pathology revealed a lobulated
grayish-yellow solid mass with a homogenous cut
surface resembling fish flesh with focal necrosis.
The spleen measured 12×11×6.5 cm, and weighed
507 g. The pathologic diagnosis was diffuse large
B-cell lymphoma, as the tumors were positive for
B-cell marker (L26/CD79a) and negative for T-cell
marker (CD3). Neck CT depicted bilateral small
lymphadenopathy along the internal jugular
chain, submental area, and level II area of the
neck, measuring 1.8×1.1 cm in maximal diame-
ter. Four days after splenectomy, the patient's
platelet counts returned to a normal level of
333,000/uL. She was staged at Ann Arbor stage
IIISEB and Ahmann stage III. After six cycles of
ProMACE-CytaBOM (cyclophosphamide, adria-
mycin, VP16, prednisone, cytarabine, bleomycin,
vincristine and methotrexate) chemotherapy, the
patient returned to Brazil and was found to be in
complete remission at the time of follow-up, 59
months after diagnosis.
DISCUSSION
The spleen serves as a complex filter to clear the
blood of particulate matter and senescent blood
cells. This organ normally weighs about 100-250 g
(average, 135 g) and usually measures 12 cm in
length, 7 cm in width, and 3 cm in thickness.
4-6
The spleen is also involved in immune defense
against blood-borne antigens.
4 More than half of
patients affected by Hodgkin's disease (HD) and
about a third of those with non-Hodgkin lym-
phoma (NHL) have splenic involvement.
7 The
splenic weight of primary splenic lymphoma
(PSL) patients is usually within the range of 226-
4,000 g, according to a report by Kraemer et al.
8 In
this study the average splenic weight was found
to be 506.3 g (range, 442-570 g). Splenic in-
volvement can be a part of diffuse dissemination
of NHL, in which the spleen is one of many in-
volved organs. Alternatively, non-Hodgkin's lym-
phoma may also originate in the spleen and then
spread to other sites.
8-10
The definition of PSL is controversial; it can be
summarized with three different definitions. Das
Gupta et al. adopted a restrictive definition of PSL
as a lymphoma involving only the spleen and the
splenic hilar lymph nodes.
11 According to this
definition, the diagnosis of PSL can only be made
if isolated splenomegaly occurs in the absence of
any other localized tumors, particularly in the
liver or the para-aortic or mesenteric lymph
nodes. Before confirming the diagnosis of PSL, the
authors recommend that a 6-month relapse-free
period should exist after removal of the spleen.
On the other hand, Skarin et al. suggested that the
diagnosis of PSL can be made if splenomegaly is
a predominant feature in any lymphoma in-
volving the spleen.
9,12,13 On the other hand,
Kraemer et al. reserved the diagnosis of PSL for
patients with splenomegaly, cytopenia of at least
two hematologic cell lines, and the absence of
peripheral adenopathy.
8 In a report by Kehoe et
al., the authors mentioned that Das Gupta's con-
ditions defined early and localized disease. These
conditions did not adequately account for other
PSL patients with more advanced disease or
disease discovered later in its course.
9 Kehoe et al.
also pointed out that a built-in survival advantage
bias existed in Das Gupta's patients and thus
chose to define PSL as NHL arising primarily in
the spleen or as NHL principally confined to the
spleen and its local lymph nodes.
9 In our report,
the first two cases are consistent with PSL with all
three definitions noted. However, in the third
case, due to multiple cervical lymphadenopathies,
the diagnosis was made using the definition by
Skarin et al. Although there cervical lymphadeno-
pathy was present, we accepted it as PSL because
the dominant tumor burden was in the spleen and
given the possibility of spread from it.
8 In addi-
tion, the possibility that the cervical lymphadeno-
pathy had an infectious origin cannot be ruled
out, in view of such symptoms on admission as
productive cough and sore throat, even if there
was no pathologically confirmed lymphoma.
Symptoms of PSL include fever, weight loss,
generalized weakness, and LUQ pain or discom-
fort from splenomegaly. There are also other
specific symptoms that result from direct invasion
of the pancreas, stomach, diaphragm, colon, or
greater omentum.
1-3,13,14 Brox et al. reported nine
cases of PSL, and splenomegaly was noted in 44%
of these patients.
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comfort was the presenting symptom in two
cases, and constitutional symptoms with multiple
small cervical lymphadenopathies were present in
the third case. The spleen was not palpable on
physical examination in any of our three cases.
Significant laboratory findings of PSL may include
cytopenia, or elevated ESR or β2-microglobulin
level.
2,3,16,17 In this report, elevated ESR and β2-
microglobulin levels were present in the first and
third cases and cytopenia was present in the third
case.
The most common appearance of PSL on diag-
nostic imaging studies is hypodense lesions on
contrast-enhanced CT scans and hypoechoic
lesions on sonography.
13,18 The differential diag-
nosis of a solitary splenic mass should include
benign entities such as haemangioma, lymphan-
gioma, hamartoma, infarct, and abscess, as well as
metastatic disease.
13,18 PSL also has a clinically rec-
ognizable pattern. However, preoperative dia-
gnosis of the condition has not been considered in
over 50% of the cases in the literature.
18,19 In our
patients, splenic lesions were hypodense, and
more clearly seen on the infused scans. Only one
of the patients showed any intra-abdominal
lymph node enlargement. Initial impressions of
the CT scans included angiosarcoma, lymphoma,
metastasis, pseudotumor, or hamartoma in these
three cases. Dachman et al. suggested that the
most common manifestation of PSL is a hypo-
dense lesion on CT and hypoechoic lesions on
sonography in symptomatic patients, those who
do not have fever or a known primary tumor
elsewhere. However, splenic biopsy or splenec-
tomy may be required for definitive diagnosis.
13
In our second unique case described here, the
tumor invaded the adjacent organs, pancreas, and
transverse colon. Karpeh et al. reported the first
case of splenic lymphoma with pathologically
documented neoplastic invasion to the colonic
mucosa.
16
If imaging studies strongly suggest the presence
of PSL, needle aspiration biopsy (NAB) or core
biopsy of the spleen may be substituted for sple-
nectomy as a diagnostic tool. These techniques
can reduce the mortality and morbidity resulting
from splenectomy; however, they are not yet
widely accepted.
7,13
In 1966, Ahmann et al. grouped PSL into three
stages depending on the extent of the disease
determined either at surgery or by other studies
in the immediate postoperative period.
1 Stage I
refers to those patients with tumor is limited to
the spleen only. Stage II patients have involve-
ment of the nodes in the splenic hilum, while
stage III patients have involvement of the liver or
lymph nodes beyond the splenic hilum. Ac-
cording to this staging system, the first case in our
study was stage I, and the second and the third
cases were stage III.
Histopathologically, all of the malignant lym-
phoma cell types can be encountered in PSL, and
are related to prognosis. In our patients, all cell
types were diffuse large B-cell lymphomas, the
most common type of NHL in Korea,
3 which were
positive for immunohistochemical stain L26.
1
Because PSL is a rare disease there are few reports
about tumor histopathologic type and patient
survival. In one study, Xiros et al. reported that 11
(38%) patients had low-grade and 18 (62%) had
intermediate or high-grade NHL.
14 Of these,
20 of
the 29 patients received splenectomies for diag-
nostic purposes, like in our cases, and only the
lymph nodes of the splenic hilum were found to
be involved in 4 patients.
14
Treatment of PSL includes splenectomy, which
also serves as a diagnostic and confirmatory
modality.
7,12,20 Although there is no clear con-
sensus, splenectomy or radiation therapy without
splenectomy might be considered if the diagnosis
can be made without splenectomy.
13 Morel et al.
and Kim et al. suggested that splenectomy could
be particularly useful in patients with prolonged
survival, primarily in those patients whose cyto-
penia resolves after surgery and in those patients
treated with adjuvant chemotherapy who are
more tolerant to the chemotherapy.
2,17 Repor-
tedly, failure to correct thrombocytopenia after
splenectomy was a poor prognostic factor.
2,17 All
the patients in this study underwent splenectomy.
Splenectomy was also used as a confirmative tool
to differentiate PSL from a splenic mass seen on
imaging studies. In the third case, the thrombocy-
topenia corrected after splenectomy concomitantly
with distal pancreatectomy and segmental resec-
tion of the transverse colon.
Unfortunately, no indications or suggestions as
to what might be the best approach to patientsJa Kyung Kim, et al.
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with primary splenic presentation following sple-
nectomy are available in the literature.
7 Aside
from splenectomy, the treatment modalities ad-
ministered in our cases included local radiation
therapy and chemotherapy. The first patient re-
ceived CHOP chemotherapy only after splenec-
tomy. The second patient received CHOP chemo-
therapy with local radiation after surgery due to
local invasion of PSL, whereas the third patient
was treated with ProMACE-CytaBOM chemo-
therapy only after splenectomy.
Presently, all three of our patients are still alive
without evidence of relapse at follow-up periods
ranging from 51 to 135 months. Although further
studies are needed, our data suggest that chemo-
therapy, with or without radiotherapy, after
splenectomy prolongs survival of PSL patients.
Ahman et al. reported that the 5-year survival
rate of all his PSL patients was 31% and 40% for
those with stage I and II. Survival of his patients
with stage I or stage II PSL was considerably bet-
ter than those with stage III.
1 However, patients
with Hodgkin's disease were also included in the
analysis.
9 In a later study by Kehoe et al., inves-
tigating the prognosis of 21 patients according to
disease stage over a 5-year period, concluded that
there was a significant difference between the
prognosis for patients with stage I or II (43%) than
those with stage III (14%).
2,9 Brox et al. reported
a median survival of 7.48 years in nine cases of
PSL.
15 In Xiros et al. documented that the median
survival in groups undergoing diagnostic splenec-
tomy was 24 months regardless of disease stage
or chemotherapeutic regimen (mainly CHOP).
14 In
our report, all three cases have survived for dura-
tions ranging from 59 to 143 months, despite the
differences in disease stage and adjuvant therapy.
Our excellent survival rates, as compared to
previous reports, may be attributed to adjuvant
chemotherapy following splenectomy in all cases
and, as for the locally advanced case, combining
radiotherapy into the treatment regime.
The prognosis for intermediate grade lym-
phoma, after splenectomy and chemotherapy, is
slightly worse than that for well-differentiated
small-cell lymphoma.
7
There is no consensus concerning the best treat-
ment for PSL. Further study is warranted to com-
pare the outcomes among the following mo-
dalities: splenectomy only, chemotherapy after
splenectomy, radiation therapy after splenectomy,
or radiation therapy with chemotherapy.
Further long-term observations of survival are
needed from more cases before any conclusions
can be drawn with respect to needle aspiration
biopsy and core biopsy of the spleen without
splenectomy.
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